肿瘤免疫治疗新进展  

New advances in tumor immunotherapy

作　　者：成春艳 王平[2] 张利斌[2] 许哲源[2] Cheng Chunyan;Wang Ping;Zhang Libin;Xu Zheyuan(School of Medicine,Kunming University of Science and Technology,Kunming,Yunnan 650500,China;The First People's Hospital of Yunnan Province,Kunming,Yunnan 650032,China)

机构地区：[1]昆明理工大学医学院,云南昆明650500 [2]云南省第一人民医院,云南昆明650032

出　　处：《医药前沿》2020年第6期5-6,共2页Journal of Frontiers of Medicine

基　　金：亚肺叶对比肺叶切除治疗≥65%Ⅰ期非小细胞肺癌的临床研究。编号:2019LCZXKF-HX03。

摘　　要：免疫疗法被喻为恶性肿瘤最有前景的治疗方法,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的使用,如抗细胞毒T淋巴细胞抗原-4(cytotoxic T lymphocyte-associated protein-4,CTLA-4)和程序性死亡因子-1(programmed death-1,PD-1)/程序性死亡因子配体-1(programmed death-ligand 1,PD-L1)单抗治疗肿瘤的方法更是以其显著的临床疗效而备受瞩目。新的免疫检查点也获得相应的突破,但目前ICIs并非所有患者均能获益,通过生物标志物筛选出可能获益的人群是目前亟需解决的问题。肿瘤免疫治疗方面获得了许多新进展,本文就肿瘤免疫治疗中的最新研究进展进行综述。Immunotherapy is regarded as the most promising treatment for malignant tumors,and the use of immunocheckpoint inhibitor(ICIs)such as anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibody in the treatment of tumor have attracted much attention because of their remarkable clinical efficacy.New immune checkpoints have also made a corresponding breakthrough.However,at present,not all patients can benefit from ICIs.It is urgent to solve the problem of immunoresistance by screening out the population that may benefit from the biomarkers.Many new advances have also been made in tumor immunotherapy.This article reviews the latest research progress in tumor immunotherapy.

关 键 词：免疫治疗 免疫检查点 生物标志物 免疫耐药 

分 类 号：R392[医药卫生—免疫学]